Osimertinib + Selumetinib for Lung Cancer

Not currently recruiting at 3 trial locations

Overseen By Pasi A Janne, MD, PhD

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Dana-Farber Cancer Institute

Must not be taking: CYP3A4 inhibitors, Vitamin E

Disqualifiers: Heart disease, CNS disease, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Breakthrough Therapy This drug has been fast-tracked for approval by the FDA given its high promise

Compensation: Varies

Number of Visits: Unknown

Duration: 2 years

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a combination of two targeted therapies, Osimertinib and Selumetinib, to determine their effectiveness in treating Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation. These drugs target specific genetic changes in the cancer to block cancer cell growth. Individuals with stage IV NSCLC with certain EGFR mutations who have not yet received treatments like chemotherapy or targeted therapies may be suitable candidates for this trial. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of participants.

Will I have to stop taking my current medications?

The trial requires that you stop taking medications that are potent inhibitors or inducers of CYP3A4, as well as high doses of supplemental vitamin E. If you are on these medications, you will need to follow specific washout times before participating.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that most people tolerate the combination of osimertinib and selumetinib well. One study found that most participants experienced only mild to moderate side effects, such as skin issues and other manageable symptoms. This suggests the combination usually doesn't cause serious problems for most people.

Osimertinib is already approved for treating certain types of lung cancer, indicating its general safety. Adding selumetinib aims to enhance treatment effects, and current evidence suggests this combination could be a promising option without major safety concerns. However, like any treatment, some risk of side effects exists. Discuss any concerns with a healthcare provider. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Researchers are excited about Osimertinib and Selumetinib for lung cancer because they target cancer cells in a unique way. Unlike standard treatments like chemotherapy, which attack rapidly dividing cells indiscriminately, Osimertinib is designed to specifically target and inhibit a mutated protein called EGFR, commonly found in lung cancer. Selumetinib, on the other hand, inhibits a pathway called MEK, potentially overcoming resistance to other treatments. This combination approach allows for a more precise attack on cancer cells, potentially leading to better outcomes and fewer side effects for patients.

What evidence suggests that this combination treatment could be effective for lung cancer?

Research has shown that osimertinib is an effective treatment for non-small cell lung cancer (NSCLC) with an EGFR mutation. Studies have found that patients taking osimertinib live for about 24.8 months on average and experience about 11.9 months before their cancer progresses. This trial examines the combination of osimertinib with another drug, selumetinib, to enhance treatment effectiveness. Early results suggest this combination might be effective because selumetinib targets a different aspect of cancer growth. This approach aims to improve outcomes for people with EGFR-mutant NSCLC by attacking the cancer more comprehensively. ^{6 7 8 9 10}

Who Is on the Research Team?

Pasi Janne

Principal Investigator

Dana-Farber Cancer Institute

Are You a Good Fit for This Trial?

This trial is for adults with stage IV Non-Small Cell Lung Cancer (NSCLC) who have specific EGFR mutations and are new to treatment. They must be in good physical condition, not pregnant or breastfeeding, willing to use contraception, and have no history of severe allergic reactions to similar drugs. Prior cancer treatments should not include EGFR-targeted therapy or chemotherapy for metastatic disease.

Inclusion Criteria

I have a tissue sample from my diagnosis available for advanced genetic testing.

I am not pregnant or breastfeeding and have confirmed this with a test or meet criteria proving I cannot become pregnant.

I am willing to use contraception or abstain from sex during and for 3 months after treatment.

Exclusion Criteria

I am allergic to medications similar to osimertinib or selumetinib.

I don't have severe side effects from previous treatments.

I haven't had any cancer except for certain skin cancers or cervical cancer in situ in the last 3 years.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive Osimertinib daily and Selumetinib intermittently (4 days on, 3 days off) to assess safety and effectiveness

2 years

Follow-up

Participants are monitored for safety and effectiveness after treatment

2 years

Clinic visits or phone calls

What Are the Treatments Tested in This Trial?

Interventions

• Osimertinib
• Selumetinib

Trial Overview

The study tests a combination of Osimertinib (Tagrisso) and Selumetinib as potential treatments for NSCLC with an EGFR mutation. It aims to see how well these two targeted therapies work together compared to current standard care.

How Is the Trial Designed?

Group I: Osimertinib + Selumetinib Experimental Treatment 2 Interventions

* Selumetinib are to be administered orally intermittently (4 days on, 3 days off) * Osimertinib are to be administered orally on a daily basis

Osimertinib is already approved in United States, European Union for the following indications:

Approved in United States as Tagrisso for:

• Locally advanced or metastatic non-small-cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R mutations
• Metastatic EGFR T790M mutation-positive NSCLC

Approved in European Union as Tagrisso for:

• Locally advanced or metastatic non-small-cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R mutations
• Metastatic EGFR T790M mutation-positive NSCLC

Who Is Running the Clinical Trial?

Dana-Farber Cancer Institute

Lead Sponsor

Trials

1,128

Recruited

382,000+

National Comprehensive Cancer Network

Collaborator

Trials

121

Recruited

7,400+

Published Research Related to This Trial

In a retrospective analysis of 32 patients with EGFR T790M-mutant non-small-cell lung cancer, osimertinib showed a 50% objective response rate and a median progression-free survival of 11.3 months, indicating its efficacy in clinical practice.

The median overall survival was 18.3 months, with better outcomes observed in patients without cerebral metastases and those with better performance status, highlighting the importance of these factors in treatment response.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Effectiveness of osimertinib in patients with lung adenocarcinoma in clinical practice - the Expanded Drug Access Program in Poland. Knetki-Wróblewska, M., Kowalski, DM., Czyżewicz, G., et al.[2022]

Osimertinib, an irreversible tyrosine kinase inhibitor, showed excellent activity in treating a 69-year-old man with metastatic EGFR-mutated non-small cell lung cancer, leading to a rapid treatment response despite initial severe pancytopenia.

After experiencing pancytopenia, the patient's dose of osimertinib was reduced from 80 mg to 40 mg daily, which allowed for continued effective treatment without further adverse events, demonstrating the potential for safe dose adjustments.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pancytopenia During Osimertinib Treatment in a Patient with EGFR-Mutated Non-Small Cell Lung Cancer. Di Marino, P., Chiapperino, C., Primavera, FC., et al.[2022]

Osimertinib (TAGRISSO) received accelerated FDA approval for treating metastatic non-small cell lung cancer with the EGFR T790M mutation, showing significant tumor response rates of 57% and 61% in two major trials involving 411 patients.

While osimertinib demonstrated promising efficacy, common side effects included diarrhea (42%) and rash (41%), with 28% of patients experiencing severe adverse events, highlighting the need for careful monitoring during treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer. Khozin, S., Weinstock, C., Blumenthal, GM., et al.[2022]

The combination of osimertinib with selumetinib or savolitinib showed a promising objective response rate of around 42-44% in patients with advanced EGFR-mutant non-small-cell lung cancer, indicating potential efficacy of these combinations.

However, combining osimertinib with durvalumab was not feasible due to a higher incidence of interstitial lung disease, highlighting safety concerns with this particular combination.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Oxnard, GR., Yang, JC., Yu, H., et al.[2022]

Osimertinib is an oral medication specifically designed to target the EGFR T790M mutation in advanced non-small cell lung cancer (NSCLC), which helps overcome resistance to previous EGFR TKI therapies.

It received accelerated approval in the USA in November 2015 for patients with metastatic EGFR T790M mutation-positive NSCLC who have progressed after EGFR TKI treatment, and is currently undergoing further development for broader treatment applications.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Osimertinib: First Global Approval. Greig, SL.[2022]

Osimertinib significantly improves disease-free survival (DFS) in adults with completely resected, early-stage EGFR mutation-positive non-small cell lung cancer (NSCLC), as shown in the pivotal ADAURA trial, regardless of prior adjuvant chemotherapy.

The treatment is well tolerated with a manageable safety profile, and it does not negatively impact health-related quality of life, making it a suitable option for adjuvant therapy in this patient population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC. Frampton, JE.[2022]

Osimertinib significantly improves progression-free survival (PFS) in patients with metastatic non-small cell lung cancer (NSCLC) with the EGFR T790M mutation, showing a median PFS of 10.1 months compared to 4.4 months with chemotherapy in a trial of 419 patients.

The safety profile of osimertinib is favorable compared to other EGFR tyrosine kinase inhibitors and chemotherapy, with common side effects including diarrhea and rash, making it a viable treatment option for patients who have progressed on previous therapies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation. Odogwu, L., Mathieu, L., Goldberg, KB., et al.[2022]

Osimertinib, a treatment for metastatic EGFRm T790M non-small-cell lung cancer, has been analyzed using newly developed and validated LC-MC/MS methods across various biological matrices, including plasma, urine, and cerebrospinal fluid.

The assays demonstrated high selectivity, accuracy, and robustness, successfully analyzing over 20,000 clinical samples, which supports the effective clinical development of osimertinib.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Determination of osimertinib in human plasma, urine and cerebrospinal fluid. Mitchell, R., Bailey, C., Ewles, M., et al.[2022]

Osimertinib (Tagrisso) is an approved adjuvant treatment for non-small cell lung cancer patients with specific tumor mutations, highlighting its targeted therapeutic approach.

Common side effects of osimertinib include blood-related issues like leukopenia and thrombocytopenia, as well as gastrointestinal and skin reactions, indicating the need for careful monitoring during treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

New Adjuvant Drug for Lung Cancer. Aschenbrenner, DS.[2023]

Citations

1.

clinicaltrials.gov

clinicaltrials.gov/study/NCT03392246

A Phase 2 Study of Osimertinib in Combination With Selumetinib ...

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer ; ClinicalTrials.gov ID NCT03392246.

2.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC7098834/

Osimertinib for Patients With Non–Small-Cell Lung Cancer ...

Here, we report the efficacy and safety of osimertinib in patients with NSCLC harboring uncommon EGFR mutations. PATIENT AND METHODS. This was a multicenter, ...

3.

nejm.org

nejm.org/doi/full/10.1056/NEJMoa2402614

Osimertinib after Chemoradiotherapy in Stage III EGFR- ...

Osimertinib is a recommended treatment for advanced non–small-cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) ...

4.

esmorwd.org

esmorwd.org/article/S2949-8201(25)00086-4/fulltext

Prognostic factors and outcomes of patients with advanced ...

Patients had real-world OS of 24.8 months and PFS of 11.9 months with first-line osimertinib. •. Corresponding OS and PFS for second-line ...

5.

ascopubs.org

ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.e21150

Efficacy and safety study of osimertinib in advanced non- ...

Efficacy and safety study of osimertinib in advanced non-small cell lung cancer (NSCLC) with EGFR mutation. Authors: Victoria García Samblás ...

6.

clinicaltrials.gov

clinicaltrials.gov/study/NCT02143466

Study Details | NCT02143466 | AZD9291 in Combination ...

Part A: To investigate the safety and tolerability of AZD9291 when given in combination with AZD6094 or selumetinib who have progressed following prior therapy ...

7.

sigma.larvol.com

sigma.larvol.com/product.php?e1=15517&tab=newstrac&page=159

Tagrisso (osimertinib) News

In conclusion, our data suggest that concomitant inhibition of both SFK/FAK and EGFR may be a promising therapeutic strategy for EGFR-mutant lung cancer. |||| ...

8.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC12294663/

Management of MET-Driven Resistance to Osimertinib in ...

TATTON: A multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Ann ...

9.

astrazenecaclinicaltrials.com

astrazenecaclinicaltrials.com/study/D6186C00001

Phase 2 Platform Study in Patients with Advanced Non- ...

A biomarker-directed Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer whose Disease Has Progressed on First-Line Osimertinib Therapy.

10.

ascopubs.org

ascopubs.org/doi/10.1200/jco.2015.33.15_suppl.2509

Preliminary results of TATTON, a multi-arm phase Ib trial ...

Adverse event (AE) data is currently available for 20 pts from all arms and cycles and includes mild/moderate AEs in 16 pts (6 skin, 5 ...